Career
Become part of the team

FDA-483 observations and warning letter citations 2019 – 2020

Share this:

John Lee, Video 2 of 9

This 2nd video (out of 9 in total) focuses on FDA Form 483 observations and Warning Letters, overall statistics for 2019 (and partly 2020) for Drug GMP.

Here you will find, a 9% increase in number of FDA-483's in 2019 compared to 2018. In absolute numbers, 779 FDA-483’s in 2019 as compared to 716 in 2018.

Top 3 issues in FDA-483’s are in 2019 (still) violation of CFR,
• 211.22(d), Quality Assurance Oversight
• 211.192, Investigations
• 211.160(b), Laboratory Control

98 Warning Letters were issued in 2019. That is an 8% increase compared to 2018. As per August 2020, 66 Warning Letters are issued.

Top 3 issues in FDA Warning Letters are,
• Validation
• QA Oversight
• Laboratory Controls

 

In general, you can access FDA's Inspection Citation database. It covers general citations, e.g. Drug, Device and Part 11 Compliance: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-citation

 

 

 

The video is recorded during the COVID-19 US lock-down by John Lee with mobile recording equipment, and the quality could be better. Focus on the great presentation and content instead.

The statistics can be downloaded as an E-book:

Read more

If you want to hear more about how Genau & More can help your company, please contact

Genau Shares

Topledelser sætter kvalitet øverst på agendaen

Kvalitet og compliance var nok ikke tidligere et begreb som trak overskrifter, og typisk blot en stabsfunktion under...

FDA-483 observations and warning letter citations 2019 – 2020

John Lee, Video 2 of 9

Showstopper GMP Violations. FDA Drug GMP

John Lee, Video 3 of 9